Compare Cytokinetics Inc (CYTK) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Estee Lauder Companies Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Estee Lauder Companies Inc trades at $93.37 (market cap $34.22B). The key difference: Estee Lauder Companies Inc is far larger — about 4× Cytokinetics Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Estee Lauder Companies Inc for 122 Days on average.
| CYTK | EL | |
|---|---|---|
Market Cap | $8.50B | $34.22B |
Volume | 2,395,556 | 2,303,792 |
Sector | Health | Consumer Staples |
52-Week High | $87.26 | $119.61 |
52-Week Low | $54.76 | $67.23 |
Typical Hold Time | 19 Days | 122 Days |
Enterprise Value | $8.60B | $39.97B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Estée Lauder (EL) trades at $94.32, up 1.03% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported a net loss of $1.13 billion in 2025 despite a high gross margin of 75.5%, while 2026 forecasts show a return to profitability. Analysts maintain a consensus buy rating with a $103 price target, supported by strategic partnerships in AI and leadership changes aimed at driving growth.
The stock's outlook is cautiously optimistic, with earnings recovery and digital initiatives offering upside, but high debt levels and margin pressures pose risks. Investor sentiment is mixed amid volatile cash flows and competitive headwinds in the beauty sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
